Shilpa Medicare’s Unit VI, Bengaluru facility has been issued UK MHRA GMP
Drug Approval

Shilpa Medicare’s Unit VI, Bengaluru facility has been issued UK MHRA GMP

The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements

  • By IPP Bureau | July 14, 2022

Shilpa Medicare Limited's newly commissioned facility for manufacture and testing of Orodispersible films and Transdermal systems situated at Dabaspet, Bengaluru, Karnataka State, has been issued GMP Certificate by UK MHRA. The facility was inspected by MHRA from 18 Apr 2022 to 20 Apr 2022.

The facility is involved in manufacturing and testing of specialized dosage forms eg. Orodispersible Films and Transdermal systems. The facility is backed up with strong Research and Development of Orodispersible films and transdermal technologies. The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements

Upcoming E-conference

Other Related stories

Startup

Digitization